001     281876
005     20251110094326.0
024 7 _ |a 10.1111/acps.70028
|2 doi
024 7 _ |a pmid:40887816
|2 pmid
024 7 _ |a 0105-0028
|2 ISSN
024 7 _ |a 0365-5067
|2 ISSN
024 7 _ |a 0065-1591
|2 ISSN
024 7 _ |a 1600-0447
|2 ISSN
024 7 _ |a 1600-5473
|2 ISSN
037 _ _ |a DZNE-2025-01247
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Solé, B.
|b 0
245 _ _ |a Unravelling the Link Between Body Mass Index and Cognitive Performance in Individuals With Bipolar Disorder and Exploration of PRS Moderation Effect: Findings From the PsyCourse Study.
260 _ _ |a Oxford [u.a.]
|c 2025
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1762764012_27494
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Bipolar disorder (BD) is a severe mental disorder characterized by extreme mood swings, often accompanied by metabolic comorbidities, such as cardiovascular disease, which increase mortality and reduce quality of life. Both metabolic dysfunctions and BD are associated with cognitive dysfunction. Body mass index (BMI) is closely linked to metabolic health and cognitive performance. This study examined the link between BMI and cognitive function in individuals with BD and how genetic factors, namely polygenic risk scores (PRS) for BD and BMI, might influence this link.Genetic (PRS scores) and phenotypic data (sociodemographic factors, clinical symptoms and cognitive function) of 341 adult patients with BD diagnosis from the PsyCourse Study, a large, multi-site, and naturalistic longitudinal study, were utilized for this study. First, we performed univariate and multivariate regression analyses to investigate associations between BMI and cognitive performance. Second, moderation analyses were conducted to examine the potential moderator effects of BD-PRS or BMI-PRS in the relationship between BMI and different cognitive outcomes.BMI was associated with processing speed (TMT-A) and executive function (TMT-B), with individuals with higher BMI showing poorer performance. Moderation analyses revealed that the effect of BMI on cognition was moderated by BD-PRS only regarding the processing speed. BMI-PRS did not moderate the association between BMI and cognitive variables.Our findings indicate that the relationship between BMI and cognitive impairment in BD is partially moderated by BD genetic liability but not by BMI genetic load.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a bipolar disorder
|2 Other
650 _ 7 |a body mass index
|2 Other
650 _ 7 |a executive function
|2 Other
650 _ 7 |a polygenic risk scores (PRS)
|2 Other
650 _ 7 |a psychomotor speed
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Bipolar Disorder: genetics
|2 MeSH
650 _ 2 |a Bipolar Disorder: physiopathology
|2 MeSH
650 _ 2 |a Bipolar Disorder: complications
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Body Mass Index
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: physiopathology
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: etiology
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: genetics
|2 MeSH
650 _ 2 |a Longitudinal Studies
|2 MeSH
650 _ 2 |a Executive Function: physiology
|2 MeSH
650 _ 2 |a Multifactorial Inheritance
|2 MeSH
700 1 _ |a Montejo, L.
|b 1
700 1 _ |a Budde, M.
|b 2
700 1 _ |a Valentí, M.
|b 3
700 1 _ |a Borràs, R.
|b 4
700 1 _ |a Martín-Parra, S.
|b 5
700 1 _ |a Ruiz, A.
|b 6
700 1 _ |a Martínez-Aran, A.
|b 7
700 1 _ |a Adorjan, K.
|b 8
700 1 _ |a Heilbronner, M.
|b 9
700 1 _ |a Navarro-Flores, A.
|b 10
700 1 _ |a Oraki Kohshour, M.
|b 11
700 1 _ |a Reich-Erkelenz, D.
|b 12
700 1 _ |a Schulte, E. C.
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Senner, F.
|b 14
700 1 _ |a Anghelescu, I. G.
|b 15
700 1 _ |a Arolt, V.
|b 16
700 1 _ |a Baune, B. T.
|b 17
700 1 _ |a Dannlowski, U.
|b 18
700 1 _ |a Dietrich, D. E.
|b 19
700 1 _ |a Fallgatter, A. J.
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Figge, C.
|b 21
700 1 _ |a Juckel, G.
|0 0000-0001-9860-9620
|b 22
700 1 _ |a Konrad, C.
|0 P:(DE-HGF)0
|b 23
700 1 _ |a Reimer, J.
|b 24
700 1 _ |a Reininghaus, E. Z.
|b 25
700 1 _ |a Schmauß, M.
|b 26
700 1 _ |a Spitzer, C.
|b 27
700 1 _ |a Wiltfang, J.
|0 P:(DE-2719)2811317
|b 28
|u dzne
700 1 _ |a Zimmermann, J.
|b 29
700 1 _ |a Falkai, P.
|b 30
700 1 _ |a Vieta, E.
|0 0000-0002-0548-0053
|b 31
700 1 _ |a Schulze, T. G.
|0 P:(DE-HGF)0
|b 32
700 1 _ |a Torrent, C.
|0 P:(DE-HGF)0
|b 33
700 1 _ |a Heilbronner, U.
|b 34
700 1 _ |a Papiol, S.
|b 35
773 _ _ |a 10.1111/acps.70028
|g Vol. 152, no. 6, p. 451 - 461
|0 PERI:(DE-600)2005703-9
|n 6
|p 451 - 461
|t Acta psychiatrica Scandinavica
|v 152
|y 2025
|x 0001-690X
856 4 _ |u https://pub.dzne.de/record/281876/files/DZNE-2025-01247.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/281876/files/DZNE-2025-01247.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 28
|6 P:(DE-2719)2811317
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-28
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1180
|2 StatID
|b Current Contents - Social and Behavioral Sciences
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0130
|2 StatID
|b Social Sciences Citation Index
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA PSYCHIAT SCAND : 2022
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-28
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-28
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ACTA PSYCHIAT SCAND : 2022
|d 2024-12-28
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1410006
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21